Business Context and Reporting Period
Impact BioMedical Inc. filed a Form 8-K reporting transactions and capital-structure changes effective October 31, 2023. The filing does not provide operating results or financial statements for a reporting period.
Key Financial Metrics and Liquidity
The filing does not provide clear values for revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
Material Changes
- Impact entered into and consummated a Share Exchange Agreement with DSS BioHealth Security, Inc. (“DBH”), its former majority shareholder.
- DBH exchanged 60,496,091 shares of common stock for 60,496,091 shares of newly issued Series A Convertible Preferred Stock.
- The Series A Preferred Stock has no dividend rights, votes alongside common stock on a one-for-one basis as converted, and is convertible at the holder’s option beginning 75 days after issuance. Each preferred share converts into one common share.
- The company effected a one-for-55 reverse split of its issued and outstanding common stock on October 31, 2023. The authorized capital stock was not subject to the reverse split, and the filing states that no amendment to the articles of incorporation or bylaws was made.
Guidance, Risks, Contingencies, and Unusual Items
- No financial guidance or operating outlook was provided.
- The preferred stock may create potential future dilution if converted into common stock, although the filing states that the shares were issued in exchange for existing common shares.
- The reverse split and preferred-stock issuance materially changed the company’s capitalization and the rights of security holders.
- Preferred holders are entitled to receive distributions from net assets available for distribution upon liquidation, dissolution, or winding up. The filing does not specify a liquidation preference amount.
- The transactions were approved by the company’s majority stockholder and board of directors.
Investor Verification Points
- Review the full Share Exchange Agreement filed as Exhibit 10.1.
- Review the Certificate of Designation for the Series A Preferred Stock filed as Exhibit 3.1.
- Verify the post-reverse-split common-stock share count and the capitalization impact of the preferred-stock issuance.
- Confirm the effective date and mechanics of the 75-day conversion period.
- Assess any subsequent filings describing conversion, ownership changes, trading effects, or additional amendments to the company’s capital structure.